- Home
- AIRT vs SPRO Comparison
AIRT vs SPRO Comparison
Compare AIRT & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- SPRO
- Stock Information
- Founded
- AIRT 1980
- SPRO 2013
- Country
- AIRT United States
- SPRO United States
- Employees
- AIRT N/A
- SPRO N/A
- Industry
- AIRT Air Freight/Delivery Services
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- AIRT Consumer Discretionary
- SPRO Health Care
- Exchange
- AIRT Nasdaq
- SPRO Nasdaq
- Market Cap
- AIRT 42.4M
- SPRO 39.2M
- IPO Year
- AIRT N/A
- SPRO 2017
- Fundamental
- Price
- AIRT $17.00
- SPRO $0.73
- Analyst Decision
- AIRT
- SPRO Buy
- Analyst Count
- AIRT 0
- SPRO 4
- Target Price
- AIRT N/A
- SPRO $5.00
- AVG Volume (30 Days)
- AIRT 3.1K
- SPRO 200.5K
- Earning Date
- AIRT 02-12-2025
- SPRO 05-14-2025
- Dividend Yield
- AIRT N/A
- SPRO N/A
- EPS Growth
- AIRT N/A
- SPRO N/A
- EPS
- AIRT N/A
- SPRO N/A
- Revenue
- AIRT $298,215,000.00
- SPRO $47,977,000.00
- Revenue This Year
- AIRT N/A
- SPRO N/A
- Revenue Next Year
- AIRT N/A
- SPRO N/A
- P/E Ratio
- AIRT N/A
- SPRO N/A
- Revenue Growth
- AIRT 3.36
- SPRO N/A
- 52 Week Low
- AIRT $14.56
- SPRO $0.51
- 52 Week High
- AIRT $30.60
- SPRO $1.72
- Technical
- Relative Strength Index (RSI)
- AIRT 52.76
- SPRO 51.21
- Support Level
- AIRT $15.84
- SPRO $0.51
- Resistance Level
- AIRT $17.43
- SPRO $0.78
- Average True Range (ATR)
- AIRT 0.68
- SPRO 0.09
- MACD
- AIRT 0.18
- SPRO 0.02
- Stochastic Oscillator
- AIRT 75.31
- SPRO 68.52
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.